ARW ON RNA
The "Middle Ground" Advantage: Why Alnylam Is Betting Big On Chemoenzymatic Ligation
Though conversations are picking up around this hybrid approach, we aren’t exactly known as an industry that embraces risk no-holds barred. While there are a handful of manufacturers and CDMOs who are embracing the hybrid model today, there are many more that are likely to hold out for the next-next gen approach: Fully enzymatic oligo production. However, as Alynlam’s CTO and Chief Quality Officer Tim Maines argued, embarking into the “middle ground” of enzymatic ligation is essential for garnering the step-by-step learnings needed to help us unlock even bigger manufacturing wins in the future.
OUR EXPERT NETWORK
-
Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit
Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.
-
Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage
Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.
-
The Evolution Of Oligonucleotide Manufacturing: Engineering Considerations For Scale, Efficiency, And Facility Design
As oligos move toward larger indications, manufacturing shifts from chemistry alone to facility design—balancing scale, solvent safety, cost, and flexibility as SPOS, slurry, and enzymatic paths converge.
-
Targeted Delivery – A Holy Grail For CRISPR Gene Editing
Precise CRISPR delivery remains the bottleneck to safer, more potent gene editing. Advances in LNP design, targeting strategies, and extrahepatic delivery are redefining what’s possible in vivo.
-
The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And Safety
Why LNPs that look identical behave differently in cells. This piece reveals how mixing physics and payload uniformity shape RNA potency, safety, dosing, and manufacturability—beyond size alone.
WEBINARS
MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
RNA HOT TAKES
VIRTUAL EVENTS
- Advancements In Targeted LNP Therapy
- Unlocking The Future: Innovations In The mRNA And Oligo Supply Chains
- Process Development Considerations For Next-Gen RNA Therapeutics
- RNA Delivery Reimagined: Innovative Nonviral Strategies Beyond LNPs
- Understanding The Impact Of New Regulatory Guidance
- A Closer Look At mRNA-LNP Analytical & Manufacturing Technology Innovation
NEWSLETTER ARCHIVE
- 03.03.26 -- Driving Fill-Finish Flexibility
- 02.25.26 -- In Vivo's Biggest Threat: A Comparison To Older Models
- 02.18.26 -- Reclaiming Efficiency In The mRNA Industry
- 02.04.26 -- Money In The Bank: Why 2025's Setbacks Were The Foundation RNA Needed
- 01.28.26 -- Manufacturing Complexities Stymie In Vivo Progress
- 01.21.26 -- Biology, Specificity, And The Rules Of RNA Business Strategy In 2026